Interferon-stimulated gene 20-kDa protein (ISG20) in infection and disease: Review and outlook

• Published in: Intractable & Rare Diseases Research Vol. 6; no. 1; pp. 35 - 40
• Main Authors: Zheng, Zhiwei, Wang, Lin, Pan, Jihong
• Format: Journal Article
• Language: English
• Published: Japan International Research and Cooperation Association for Bio & Socio-Sciences Advancement 01-01-2017
• Subjects: antiviral; clinical use; exonuclease; interferon-stimulated gene; ISG20; Mini-Review; ISG20; clinical use; interferon-stimulated gene; exonuclease; antiviral
• ISSN: 2186-3644; 2186-361X
• DOI: 10.5582/irdr.2017.01004

Interferon-stimulated exonuclease gene 20 (ISG20) is an RNA exonuclease in the yeast RNA exonuclease 4 homolog (REX4) subfamily and the DEDDh exonuclease family, and this gene codes for a 20-kDa protein. Those exonucleases are involved in cleaving single-stranded RNA and DNA. ISG20 is also referred to as HEM45 (HeLa estrogen-modulated, band 45). Expression of ISG20 can be induced or regulated by both type I and II interferons (IFNs) in various cell lines. ISG20 plays a role in mediating interferon's antiviral activities. In addition, ISG20 may be a potential susceptibility biomarker or pharmacological target in some inflammatory conditions. Exonucleases are useful components of many physiological processes. Despite recent advances in our understanding of the functions of ISG20, much work remains to be done with regard to uncovering the mechanism of action of ISG20 in specific diseases and adapting ISG20 for use as a biomarker of disease. This review describes current information on ISG20 and its potential use in marking disease. This review describes several research achievements thus far and it seeks to provide some new ideas for future related research.